Update Your Profile Member Spotlights Refer a Member: IASP Champions Join a Special Interest Group (SIG) Find a Chapter Join Now
PAIN PAIN Reports Pain Research Forum Papers of the Week Webinars and Podcasts Events
Online Learning - PERC Webinars & Podcasts Curricula Graduate Opportunities Events
RELIEF News Resources for Living with Pain Global Alliance of Partners in Pain Advocacy (GAPPA) Events
Support IASP Sponsor an Event Become a Partner
< BACK TO ARCHIVE
POW ARCHIVE WEEK: Papers: 30 May 2020 - 5 Jun 2020
STUDY TYPE:Human Studies, Pharmacology/Drug Development
PAIN TYPE:Itch
DATE PUBLISHED: 2020 Jun 03
JOURNAL:JAMA Dermatol
PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/32492087?dopt=Abstract
Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic dermatitis (AD).
